These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 38240949)

  • 1. Dapagliflozin Utilization in Chronic Kidney Disease and Its Real-World Effectiveness Among Patients with Lower Levels of Albuminuria in the USA and Japan.
    Tangri N; Rastogi A; Nekeman-Nan C; Hong LS; Ozaki A; Franzén S; Sofue T
    Adv Ther; 2024 Mar; 41(3):1151-1167. PubMed ID: 38240949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
    Jongs N; Greene T; Chertow GM; McMurray JJV; Langkilde AM; Correa-Rotter R; Rossing P; Sjöström CD; Stefansson BV; Toto RD; Wheeler DC; Heerspink HJL;
    Lancet Diabetes Endocrinol; 2021 Nov; 9(11):755-766. PubMed ID: 34619106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
    Zelniker TA; Raz I; Mosenzon O; Dwyer JP; Heerspink HHJL; Cahn A; Goodrich EL; Im K; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Gause-Nilsson I; Langkilde AM; Sabatine MS; Wiviott SD
    JAMA Cardiol; 2021 Jul; 6(7):801-810. PubMed ID: 33851953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
    Heerspink HJL; Jongs N; Chertow GM; Langkilde AM; McMurray JJV; Correa-Rotter R; Rossing P; Sjöström CD; Stefansson BV; Toto RD; Wheeler DC; Greene T;
    Lancet Diabetes Endocrinol; 2021 Nov; 9(11):743-754. PubMed ID: 34619108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b-4 chronic kidney disease.
    Dekkers CCJ; Wheeler DC; Sjöström CD; Stefansson BV; Cain V; Heerspink HJL
    Nephrol Dial Transplant; 2018 Nov; 33(11):2005-2011. PubMed ID: 29370424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Albuminuria-Lowering Effect of Dapagliflozin, Eplerenone, and Their Combination in Patients with Chronic Kidney Disease: A Randomized Crossover Clinical Trial.
    Provenzano M; Puchades MJ; Garofalo C; Jongs N; D'Marco L; Andreucci M; De Nicola L; Gorriz JL; Heerspink HJL; ;
    J Am Soc Nephrol; 2022 Aug; 33(8):1569-1580. PubMed ID: 35440501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial.
    Pollock C; Stefánsson B; Reyner D; Rossing P; Sjöström CD; Wheeler DC; Langkilde AM; Heerspink HJL
    Lancet Diabetes Endocrinol; 2019 Jun; 7(6):429-441. PubMed ID: 30992195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics.
    Wheeler DC; Stefansson BV; Batiushin M; Bilchenko O; Cherney DZI; Chertow GM; Douthat W; Dwyer JP; Escudero E; Pecoits-Filho R; Furuland H; Górriz JL; Greene T; Haller H; Hou FF; Kang SW; Isidto R; Khullar D; Mark PB; McMurray JJV; Kashihara N; Nowicki M; Persson F; Correa-Rotter R; Rossing P; Toto RD; Umanath K; Van Bui P; Wittmann I; Lindberg M; Sjöström CD; Langkilde AM; Heerspink HJL
    Nephrol Dial Transplant; 2020 Oct; 35(10):1700-1711. PubMed ID: 32862232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58.
    Mosenzon O; Wiviott SD; Heerspink HJL; Dwyer JP; Cahn A; Goodrich EL; Rozenberg A; Schechter M; Yanuv I; Murphy SA; Zelniker TA; Gause-Nilsson IAM; Langkilde AM; Fredriksson M; Johansson PA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS; Raz I
    Diabetes Care; 2021 Aug; 44(8):1805-1815. PubMed ID: 34233928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease.
    Chertow GM; Vart P; Jongs N; Toto RD; Gorriz JL; Hou FF; McMurray JJV; Correa-Rotter R; Rossing P; Sjöström CD; Stefánsson BV; Langkilde AM; Wheeler DC; Heerspink HJL;
    J Am Soc Nephrol; 2021 Sep; 32(9):2352-2361. PubMed ID: 34272327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dapagliflozin and Blood Pressure in Patients with Chronic Kidney Disease and Albuminuria.
    Heerspink HJ; Provenzano M; Vart P; Jongs N; Correa-Rotter R; Rossing P; Mark PB; Pecoits-Filho R; McMurray JJ; Langkilde AM; Wheeler DC; Toto RB; Chertow GM
    Am Heart J; 2024 Apr; 270():125-135. PubMed ID: 38367893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial.
    Wheeler DC; Jongs N; Stefansson BV; Chertow GM; Greene T; Hou FF; Langkilde AM; McMurray JJV; Rossing P; Nowicki M; Wittmann I; Correa-Rotter R; Sjöström CD; Toto RD; Heerspink HJL;
    Nephrol Dial Transplant; 2022 Aug; 37(9):1647-1656. PubMed ID: 34850160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of dapagliflozin on volume status and systemic haemodynamics in patients with chronic kidney disease without diabetes: Results from DAPASALT and DIAMOND.
    Sen T; Scholtes R; Greasley PJ; Cherney DZI; Dekkers CCJ; Vervloet M; Danser AHJ; Barbour SJ; Karlsson C; Hammarstedt A; Li Q; Laverman GD; Bjornstad P; van Raalte DH; Heerspink HJL
    Diabetes Obes Metab; 2022 Aug; 24(8):1578-1587. PubMed ID: 35478433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial.
    Heerspink HJL; Stefansson BV; Chertow GM; Correa-Rotter R; Greene T; Hou FF; Lindberg M; McMurray J; Rossing P; Toto R; Langkilde AM; Wheeler DC;
    Nephrol Dial Transplant; 2020 Feb; 35(2):274-282. PubMed ID: 32030417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved home BP profile with dapagliflozin is associated with amelioration of albuminuria in Japanese patients with diabetic nephropathy: the Yokohama add-on inhibitory efficacy of dapagliflozin on albuminuria in Japanese patients with type 2 diabetes study (Y-AIDA study).
    Kinguchi S; Wakui H; Ito Y; Kondo Y; Azushima K; Osada U; Yamakawa T; Iwamoto T; Yutoh J; Misumi T; Aoki K; Yasuda G; Yoshii T; Yamada T; Ono S; Shibasaki-Kurita T; Hosokawa S; Orime K; Hanaoka M; Sasaki H; Inazumi K; Yamada T; Kobayashi R; Ohki K; Haruhara K; Kobayashi Y; Yamanaka T; Terauchi Y; Tamura K
    Cardiovasc Diabetol; 2019 Aug; 18(1):110. PubMed ID: 31455298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of zibotentan and dapagliflozin in patients with chronic kidney disease: study design and baseline characteristics of the ZENITH-CKD trial.
    Heerspink HJL; Greasley PJ; Ahlström C; Althage M; Dwyer JP; Law G; Wijkmark E; Lin M; Mercier AK; Sunnåker M; Turton M; Wheeler DC; Ambery P
    Nephrol Dial Transplant; 2024 Feb; 39(3):414-425. PubMed ID: 37632201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial.
    EMPA-KIDNEY Collaborative Group
    Lancet Diabetes Endocrinol; 2024 Jan; 12(1):39-50. PubMed ID: 38061371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial.
    Heerspink HJL; Kiyosue A; Wheeler DC; Lin M; Wijkmark E; Carlson G; Mercier AK; Åstrand M; Ueckert S; Greasley PJ; Ambery P
    Lancet; 2023 Nov; 402(10416):2004-2017. PubMed ID: 37931629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial.
    Waijer SW; Vart P; Cherney DZI; Chertow GM; Jongs N; Langkilde AM; Mann JFE; Mosenzon O; McMurray JJV; Rossing P; Correa-Rotter R; Stefansson BV; Toto RD; Wheeler DC; Heerspink HJL
    Diabetologia; 2022 Jul; 65(7):1085-1097. PubMed ID: 35445820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Class effects of SGLT2 inhibitors on cardiorenal outcomes.
    Kluger AY; Tecson KM; Lee AY; Lerma EV; Rangaswami J; Lepor NE; Cobble ME; McCullough PA
    Cardiovasc Diabetol; 2019 Aug; 18(1):99. PubMed ID: 31382965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.